OncoPharm artwork

Adjuvant Abemaciclib

OncoPharm

English - October 14, 2021 19:57 - 16 minutes - 13.4 MB - ★★★★★ - 122 ratings
Science Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed


FDA approves 2-years of abemaciclib plus endocrine therapy for high-risk HR+, HER2(-) patients. Quite a bit to discuss about this. Also, FDA expands indications for pembrolizumab (of course) and brexucabtagene autoleucel.

NOTE: A 5cm breast tumor is a T3 lesion, not a T2 as misstated in this episode.